Blaze Bioscience Secures $5M Series A

Blaze Biosciences, Inc. , a privately held biotechnological company dedicated to the development of products that assist surgeons in their quest to improve the lives of cancer patients, today announced that the company has raised $5 million in Series A funding. The new funds will be used to further advance the company’s Tumor Paint technology, which originated in and licensed from the laboratory of one of Blaze Bioscience’s founders, Dr. Jim Olson of the Fred Hutchinson Cancer Research Centre

Blaze Bioscience is developing Tumor Paint for real-time, high-resolution visualization of a wide range of solid tumors. By binding to and illuminating cancer cells, Tumor Paint may allow surgeons to see and remove cancerous tissue that might otherwise have been undetected. The ability to view tumor margins more precisely during surgery may also allow critical normal tissue, such as the nerve or brain, to be spared. With surgery remaining the primary form of cancer therapy and often offering the greatest chance of recovery, Tumor Paint has the potential to transform cancer surgical treatment.

“This funding is an important milestone for Blaze Bioscience It will allow the company to move from the seed stage to the full execution mode by moving Tumor Paint into development, including product scale and toxicology studies, on schedule,” said Heather Franklin, Co-Founder, President and Chief Executive Officer.

“We are very pleased to have raised the capital necessary to move Tumor Paint forward. We remain inspired by the needs of pediatric patients with cerebral cancer for whom the technology has been developed and look forward to the possibility of extending the use of Tumor Paint to major solid tumors,” said Dr. Jim Olson, Blaze Bioscience Co-Founder and Member of the Board

About Blaze Bioscience, the Company of Tumor Paint
Blaze Biosciences, Inc. Seattle is a privately held biotechnological company dedicated to the development of products that help surgeons to improve the lives of cancer patients. The company was founded in 2010 to develop and market the technology of Tumor Paint. Tumor Paint provides real-time, high-resolution intraoperative visualization of cancer cells, allowing for better detection and more complete and accurate cancer surgical resection. The first Tumor Paint product candidate, a combination of peptide targeting and fluorescent beacon, is under development for multiple solid tumors.

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Blaze%20Bioscience/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co